Navigation Links
CORDIS Launches ExoSeal(TM) Vascular Closure Device
Date:5/27/2010

PARIS, May 27, 2010 /PRNewswire/ --

- New Trial Results on ExoSeal(TM) Vascular Closure Device Support its Clinical Safety* and Efficacy

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis Corporation received CE-Marking approval for ExoSeal(TM) Vascular Closure Device in May 2010. This new product was launched during EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

ExoSeal(TM) was shown in a recent clinical trial to have an excellent clinical safety* profile during vascular procedures. The 'ECLIPSE Trial' recorded no adverse clinical events and achieved a level of safety comparable to manual compression while significantly reducing time to ambulation. The device has achieved this level of clinical safety by combining easy-to-use functionality with trusted bioabsorbable technology and precise extravascular closure.

"We are very pleased to announce the launch of our first Vascular Closure Device" said Campbell Rogers, M.D., Chief Scientific Officer and Global Head, Research and Development, Cordis Corporation. "The ExoSeal(TM) Vascular Closure Device incorporates key advancements including the use of the Polyglycolic Acid Plug, two visual indicators to moderate control of the device and lockout features to reduce the risk of complications. The device is designed for ease of use, reducing the number of components and deployment s
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Court of Appeals Overturns 2005 Patent Verdict Against Cordis
2. MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer
3. Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley
4. RURO Launches FreezerPro MultiSite
5. ASU Nursing and Health Launches Regulatory Science and Health Safety Masters Program
6. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
7. Biomatrica Launches New Partnership Program - Biomatrica Connect(TM)
8. VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
9. BellBrook Labs Launches Compound Profiling Services with High Content 3D Invasion Assay
10. Ansell Launches Worldss First Antimicrobial Surgical Glove
11. ChromaDex Launches pTeroPure Pterostilbene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... MA (PRWEB) October 25, 2014 ... products, is pleased to announce the release of ... the highest level of contamination containment in critical ... Class 3 and higher cleanroom environments, ValuSeal® IonX™ ... polyester knit laundered wiper that continues Berkshire’s innovative ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... Oct. 22, 2014 Research and ... "Global DNA Diagnostics Market (Product types, Application, ... Global Trends, Company Profiles, Demand, Insights, Analysis, Research, ... report to their offering. ... applications, techniques, end users and Geography) Global Size, ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... SHANGHAI, June 16 /PRNewswire-Asia/ -- ... announced,today that its animal facility in Shanghai has passed ... Sundia management and staff are praised,for providing good facilities ... , The inspection and audit ...
... June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: ... of its,recently completed international Phase III trial of Bronchitol in ... Cystic Fibrosis,Conference in Brest, France. , ... June by Dr Diana,Bilton of the Royal Brompton Hospital, London. ...
... , DETROIT, June 15 Business, nonprofit and ... the manufacturing sector that includes enacting pro-industry policies and ... investment, and creating new demand through innovation and globalization. ... at The National Summit in Detroit agreed that economic ...
Cached Biology Technology:Sundia's Animal Facility Passed Client and Government Inspection 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 2Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 3
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... One in eight women in the United States will receive ... is the second leading cause of cancer-related death in women. ... possible treatment for each patient. "Our research shows that ... without getting any treatment at all, other than a lumpectomy," ...
... mobile phone charger at home when you go for ... norm one day as scientists from Nanyang Technological University ... a microchip that uses 30 times less electricity while ... The technology, dubbed PCMOS (probabilistic complementary metal-oxide semiconductor) was ...
... of genetic factors associated with heart attacks has identified ... that appear to increase the risk for early-onset myocardial ... Consortium, based on information from a total of 26,000 ... Genetics and is receiving early online release. ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 3International study identifies gene variants associated with early heart attack 2International study identifies gene variants associated with early heart attack 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... the Beacon 2000 instrument can be used ... Beacon 2000 Data Manager Software provides the ... directly from the instrument. These data can ... available spreadsheets, such as Microsoft Excel or ...
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... self locking design in ice/water bath ... product number, created to easily match ... availability yet, please order under the ... customer service for assistance. ID clarifier: ...
Biology Products: